Schellens JHM - Search Results

1

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Juric D, et al. Among authors: schellens jhm. J Clin Oncol. 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. Epub 2018 Feb 5. J Clin Oncol. 2018. PMID: 29401002 Free PMC article. Clinical Trial.

2

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J. Mackean M, et al. J Clin Oncol. 1998 Sep;16(9):2977-85. doi: 10.1200/JCO.1998.16.9.2977. J Clin Oncol. 1998. PMID: 9738566 Clinical Trial.

3

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast GC, Beijnen JH, Schellens JH. Crul M, et al. J Clin Oncol. 2002 Jun 1;20(11):2726-35. doi: 10.1200/JCO.2002.09.116. J Clin Oncol. 2002. PMID: 12039935 Clinical Trial.

4

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. Kruijtzer CM, et al. J Clin Oncol. 2002 Jul 1;20(13):2943-50. doi: 10.1200/JCO.2002.12.116. J Clin Oncol. 2002. PMID: 12089223 Clinical Trial.

5

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.

Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW. Crul M, et al. Eur J Cancer. 2002 Aug;38(12):1615-21. doi: 10.1016/s0959-8049(02)00127-2. Eur J Cancer. 2002. PMID: 12142051 Clinical Trial.

6

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathôt RA, Marcus S, van Tinteren H, Baas P. Kruijtzer CM, et al. J Clin Oncol. 2002 Dec 1;20(23):4508-16. doi: 10.1200/JCO.2002.04.058. J Clin Oncol. 2002. PMID: 12454106 Clinical Trial.

7

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH. Crul M, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3526-33. Clin Cancer Res. 2003. PMID: 14506138 Clinical Trial.

8

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.

Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP. Rademaker-Lakhai JM, et al. Clin Cancer Res. 2004 May 15;10(10):3386-95. doi: 10.1158/1078-0432.CCR-03-0315. Clin Cancer Res. 2004. PMID: 15161693 Clinical Trial.

9

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH. Rademaker-Lakhai JM, et al. Clin Cancer Res. 2004 Jun 1;10(11):3717-27. doi: 10.1158/1078-0432.CCR-03-0746. Clin Cancer Res. 2004. PMID: 15173078 Clinical Trial.

10

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.

Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH. Schoemaker NE, et al. Cancer Chemother Pharmacol. 2005 Mar;55(3):263-70. doi: 10.1007/s00280-004-0874-2. Epub 2004 Nov 16. Cancer Chemother Pharmacol. 2005. PMID: 15592838 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

754 results

Search Page

Filters